Bipolar Organic Polymer for High Performance Symmetric Aqueous Proton Battery.

Bipolar electroactive organic molecules receive an increasing research attention as electrode materials for rechargeable batteries due to their flexibility, controllability, and environmental friendliness. While its application for symmetric aqueous proton batteries is still in its infancy. Herein, a symmetric aqueous proton battery (APB) based on a bipolar poly(aminoanthraquinone) (PNAQ) is developed. The conductivity and solubility of PNAQ are significantly improved by introducing a polyaniline-like skeleton. It is demonstrated that the quinone-based moieties allow H+ reversible uptake/removal and the benzene ring-based units achieve HSO4 - adsorption/desorption. The fabricated symmetric APB exhibits a high discharge capacity of 85.3 mA h g-1 at 5 C and excellent rate performance (77 mA h g-1 at 100 C). The good rate performance benefits from capacitance-like ions diffusion mechanism. Furthermore, surprisingly, the system can also operate at -70 °C and shows superior electrochemical performance (60.4 mA h g-1 at -70 °C).

Diagnosis and treatment of eosinophilic myocarditis.

Eosinophilic myocarditis is a type of inflammatory cardiomyopathy characterized by eosinophilic infiltration into myocardial tissue. The accurate myocarditis incidence rate is difficult to determine because of the clinical limitations of an endomyocardial biopsy. The primary pathogenesis of eosinophilic myocarditis is the release of related substances by eosinophils, leading to cell membrane damage and cell destruction. However, evidence suggests that specific genes play a role in myocarditis development.As CMR imaging availability increases, the diagnosis rate of eosinophilic myocarditis will increase. The diagnosis of myocarditis mainly depends on an endocardial biopsy. Glucocorticoids can relieve patients' symptoms, but the early use of steroids may prevent intermediate disease stage development (i.e., thrombonecrosis and fibrosis with wall thrombosis). Anticoagulant therapy may also affect disease development. In addition to routine follow-up, a regular myocardial biopsy should be considered for discharged patients, if possible.

Electrocardiogram signs of right ventricular hypertrophy may help identify pulmonary hypertension in patients with dilated cardiomyopathy.

OBJECTIVE: To the authors' knowledge, limited data are available regarding the association between Electrocardiogram (ECG) signs of right ventricular hypertrophy (RVH) and pulmonary hypertension (PH) in patients with dilated cardiomyopathy (DCM). We aimed to assess the accuracy of the recommended ECG criteria of RVH for predicting PH in patients with DCM. METHODS: According to the definition of PH (mPAP ≥ 25 mm Hg), 35 patients with DCM were divided into 2 groups: DCM with PH (n = 22) and DCM without PH (n = 13). Right heart catheterization was performed in all patients. Seventeen parameters of RVH recommended by the AHA/ACCF/HRS for diagnosis of RVH on ECG were determinded. RESULTS: The following parameters were correlated with mPAP: RV1 > 6 mm, SV5 > 10 mm, R:SV6 < 0.4, RV1 + SV5 or V6 > 10.5 mm and PII amplitude. The following parameters were significantly different between DCM patients with and without PH: S in V5 (SV5) > 10 mm, S in V6 (SV6) > 3 mm, R:S ratio in V5 (R:SV5) < 0.75, RV1 + SV5 or V6 > 10.5 mm, S > R inI, S > R inII and R:S V1 > R:S V3, although results were no longer significant after correcting for multiple comparisons. High specificity (92.3-100%), lowsensitivity (31.8-50%), high positive predictive value, and low negative predictive value of established parameters of RVH were noted for predicting PH in patients with DCM. CONCLUSION: Several ECG signs of RVH may be useful for in the diagnosis PH in patients with DCM.